Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2024 Sep 27;25(1):316.
doi: 10.1186/s12882-024-03713-9.

Safety and efficacy of sparsentan versus irbesartan in focal segmental glomerulosclerosis and IgA nephropathy: a systematic review and meta-analysis of randomized controlled trials

Ahmed A Abo Elnaga  1 , Mohamed A Alsaied  1 , Abdelrahman M Elettreby  1 , Alaa Ramadan  2 , Mohamed Abouzid  3   4 , Raghda Shetta  5 , Yazan A Al-Ajlouni  6
Affiliations
Meta-Analysis

Safety and efficacy of sparsentan versus irbesartan in focal segmental glomerulosclerosis and IgA nephropathy: a systematic review and meta-analysis of randomized controlled trials

Ahmed A Abo Elnaga et al. BMC Nephrol. .

Abstract

Background: Sparsentan has shown positive effects on managing different subtypes of glomerulonephritis. The recent results of trials require a pooled analysis to validate these results.

Aim: We aim to assess the safety and efficacy of sparsentan versus irbesartan for patients with IgA nephropathy and focal glomerulosclerosis (FSGS).

Methods: We conducted a systematic review and meta-analysis of randomized controlled trials retrieved by systematically searching PubMed, Web of Science, Scopus, and Cochrane through March 2024. We used Review Manager v.5.4 to pool dichotomous data using risk ratio (RR) and continuous data using mean difference (MD) with a 95% confidence interval (CI).

Results: Three studies with a total of 884 patients were included. Sparsentan was superior to irbesartan in improving urine protein to creatinine ratio (UP/C) (ratio of percentage reduction 0.66, 95% CI [0.58 to 0.74], P < 0.001); as well as the proportion of patients achieved complete and partial remission of proteinuria (RR = 2.57, 95% CI [1.73 to 3.81], P < 0.001) and (RR = 1.63, 95% CI [1.4 to 1.91], P < 0.001) respectively. Regarding the effect on the glomerular filtration rate, the results estimate did not favor either sparsentan or irbesartan (MD = 1.98 ml/min per 1.73mm2, 95% CI [-1.05 to 5.01], P = 0.2). There were no significant differences in adverse events except for hypotension, which showed higher rates in the sparsentan group (RR = 2.02, 95% CI [1.3 to 3.16], P = 0.002).

Conclusion: Sparsentan is effective and has a good safety profile for treating FSGS and patients with IgA nephropathy. However, more well-designed RCTs against ARBs, ACE inhibitors, and steroids with larger sample sizes are needed to get conclusive evidence.

Keywords: ACE inhibitors; ARBs; Dual endothelin; Focal glomerulosclerosis; IgA nephropathy; Sparsentan.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
PRISMA diagram of study selection process
Fig. 2
Fig. 2
Forest plot showing the change in UP/C ratio from baseline
Fig. 3
Fig. 3
Forest plot showing the percentage of patients achieving complete remission of proteinuria
Fig. 4
Fig. 4
Forest plot showing the percentage of patients achieving partial remission of proteinuria
See this image and copyright information in PMC

References

    1. Keskinyan VS, Lattanza B, Reid-Adam J. Glomerulonephritis Pediatr Rev. 2023;44:498–512. - PubMed
    1. Wetmore JB, Guo H, Liu J, Collins AJ, Gilbertson DT. The incidence, prevalence, and outcomes of glomerulonephritis derived from a large retrospective analysis. Kidney Int. 2016;90:853–60. - PubMed
    1. Ștefan G, Zugravu A, Stancu S. Mortality in IgA nephropathy: a long-term Follow-Up of an eastern European cohort. Med (Mex). 2024;60:247. - PMC - PubMed
    1. Kiffel J, Rahimzada Y, Trachtman H. Focal segmental glomerulosclerosis and chronic kidney Disease in Pediatric patients. Adv Chronic Kidney Dis. 2011;18:332–8. - PMC - PubMed
    1. Schena FP, Nistor I. Epidemiology of IgA Nephropathy: A Global Perspective. Semin Nephrol. 2018;38:435–42. - PubMed

MeSH terms

Substances

LinkOut - more resources